INTRODUCTION
The identification and cloning of human and mouse cDNAs with high degrees of similarity to amyloid precursor protein (APP), the protein from which the f6-amyloid polypeptide found in senile plaques in Alzheimer's disease brain is derived, indicated that this protein is a member of a larger gene family [1] [2] [3] . The 653-amino acid amyloid precursor protein-like protein (APLP)1 is 42 % identical with 64 % similar to that of the 695-amino acid APP (APP-695) [1] , and APLP2 (also termed APPH) is predicted to be a 763-amino acid protein with an amino acid sequence 52 % identical with 71 % similar to APP-751 [2] . APLP2 has an amino acid sequence 43 % identical with 63 % similar to APLP1. Virtually all ofthe identified domains and motifs that characterize APP are present in APLP1 and APLP2 including a hydrophobic membrane-spanning domain, N-glycosylation sites and a Kunitz protease inhibitory (KPI) domain. It has also been reported that APLP2 enters a secretory pathway and that soluble APLP2 derivatives are secreted by transfected cells of neuronal and nonneuronal origin [4] . These similarities between APLP2 and APP imply that APLP2 may have many of the as yet not fully characterized functions of APP. However, the lack of the fiamyloid domain in APLP1 and APLP2 indicates that these proteins cannot act as substrates for the deposition of fl-amyloid in Alzheimer's disease.
High levels of APLP2 mRNA expression have been reported in mouse brain and peripheral tissue [4] as well as human brain, with highest expression in the temporal association cortex [2] . The relative expression of APLP2 mRNA to that of APP has been estimated as 0.55 [4] . The similarity of these proteins raises the problem of distinguishing between them with the use of antibodies; indeed, it was recently demonstrated that widely used immunological reagents generated against APP immunogens fail to discriminate APP from APLP2 [4] . For [7] , and ventricular CSF (VCSF) from two patients with bipolar depression undergoing psychosurgery. All were prepared for electrophoresis as described [8] .
PC12 cells (ATCC, CRL 1721; Porton Down, Wilts., U.K.) were grown [9] buffer, sonicated and centrifuged (12000 g for 15 min) before electrophoresis. Concentrated medium (6 x ; Centricon 10 tubes; Amicon, Stonehouse, Gloucestershire, U.K.) was mixed with concentrated sample buffer to allow for dilution. Oxidative stress was produced as previously described [9] by treatment of PC12 cells for 3 h with 5 mM deoxyglucose and 0.2 ug/ml oligomycin in glucose-and pyruvate-free medium.
Cultures of neurons from the cerebellum and cerebral cortex were prepared from 7-day-old and embryonic (El 7) rats respectively and grown by the method of Dutton and Tear [10] . After 7 or 12 days respectively in vitro, cells were exposed to 500,M glutamate for 30 min and the cells placed in fresh medium (1.5 ml) for a further 24 h. Medium from both culture types was concentrated (2.5 x; Centricon 10 tubes) and cell supernatant, obtained by freezing and thawing cells in distilled water followed by centrifugation (11000 g; 10 min), was mixed with concentrated sample buffer to allow for dilution. Neuroblastoma cells (SH-SY5Y) were grown as previously described [11] and cell lysate prepared for electrophoresis as above.
H4 human neuroglioma cells were stably transfected with mouse APLP1 [1] or human APLP2-763 [2] cloned into a mammalian expression vector containing the CM promoter sequence (pRcCMV; Invitrogen). Cells were maintained in DMEM supplemented with 10% fetal calf serum, 1 % Lglutamine, 1 % penicillin/streptomycin and, where appropriate, G418 selection (150 #l/ml). To harvest protein, cells were washed in Hanks buffered saline (Gibco/BRL) and processed for electrophoresis (as above). Cells transfected with either APLP1 or APLP2 overexpress the expected mRNA (analysed by Northern blot [12] ). In addition, using the appropriate polyclonal antibody (D2-1 [13] ), APLP2 was overexpressed in cell lysate (W. Wasco, K. M. Felsenstein and R. E. Tanzi, unpublished work).
Sequences that encode residues 562-681 of mouse APLP2-751 [4] were generated by PCR using a sense primer, 5'-CCGGGA-TCCGATGAGCTCCTTCAGGAAC-3' and an antisense primer 5'-CCGGAATTCATTGCTGCTCAAACTGAAATCC-3', and mouse APLP2 cDNA [4] as the template. The PCR product was digested with BamHI and EcoRI, gel-purified and subsequently ligated to plasmid pGEX-2T [14] previously digested with BamHI and EcoRI. The resulting plasmid, pGEX-AAPLP2, encodes 120 amino acids that are immediately Nterminus to the transmembrane domain of APLP2-751, as a Cterminal fusion protein with glutathione S-transferase (GST). The GST fusion protein was expressed and purified as described [14] . COS-1 cells were transiently transfected with mouse APLP2-751 cDNA, and lysates were prepared as described [13] .
Purified secreted APP-695 from transfected 293 cells [15] and baculovirus-expressed APP-751 [16] were gifts from Dr. D. Schenk (Athena Neurosciences, South San Francisco, CA, U.S.A.). Cell lysate from Chinese hamster ovary cells transfected with mouse APLP2 was as previously described [4] and was prepared for electrophoresis (as above). Monoclonal antibody 22C1 1 [17] was obtained commercially (Boehringer, Lewis, Sussex, U.K.).
Production of a monoclonal antibody to APLP2
From a 98-amino acid sequence of the ectodomain of APLP2 (amino acids 566-664; Figure 1 ), overlapping tetradecapeptide sequences were synthesized using a previously published method with the addition of a terminal cysteine residue to facilitate coupling to a heterobifunctional agent [18] . Peptides were evaluated for purity by reverse-phase HPLC and plasma-desorption MS (Bio-Ion 20) and subsequently coupled to tuberculin [18] . Female Balb/c mice were primed with a subcutaneous injection of human BCG vaccine [19] , followed by three booster immunizations (subcutaneously) ofpeptide-tuberculin conjugate in Freund's incomplete adjuvant at 3-week intervals. Groups of three mice each received injections of two overlapping peptide conjugates, e.g. B4 and C4 (Figure 1 ). After 10 days the mice were bled and serum was screened by electrophoresis and Western blotting to identify high responders. The selected mice [previously injected with peptides B4/C4 (Figure 1 )] were given intraperitoneal and intravenous boosts of peptide-tuberculin conjugate (50 ,l) on each of the 2 days before spleen removal. The spleens were removed aseptically, and the spleenocytes fused with Sp2 myeloma cells as previously described [20] . The resulting hybridomas were suspended and diluted, then plated out in 96-well tissue culture plates. After 2). This was also a feature of 22C1 1 immunoreactivity (Figure 4 ) (see also ref. [9] ). A single high-molecular-mass immunoreactive band (about 120 kDa) was observed in conditioned medium from PC12 cells (Figure 2d, lane 3) and the primary cultures (Figure 2d, lanes 13  and 15) . The release of APLP2 into conditioned medium of PC12 cells was stimulated by NGF (400 ng/ml for 3 days; Figure 2d , compare lanes 3 and 8) in a time-dependent manner ( Figure  2d, lanes 4-8) and bradykinin (500 nM for 3 or 6 h; Figure 2d , compare lanes 9 and 10, and 11 and 12). However (Figure 2d, compare lanes 16 and 18) and cerebellar granule cells (not shown).
The identification of APLP2 in conditioned medium and cerebrospinal fluid suggests that APLP2 may be processed both in vitro and in vivo to produce a soluble secreted truncated form of the protein. The control of this secretory pathway appears to be qualitatively similar to that for APP (Figure 2 ; see also refs. [9, 23] ) as both NGF and bradykinin increase the appearance of APLP2 in conditioned medium. However, whereas 22C1 1 immunoreactivity was easily detectable in medium after 1 h, the same was not true for APLP2. Thus 3 days incubation of PC12 cells (absence of NGF; Figure 2d , lane 3) or 3 h (presence of NGF, Figure 2d , lane 4) was required for detection of APLP2 in conditioned medium. Similarly, 3 h treatment of PC12 cells with bradykinin was required to see clearly an effect on APLP2 secretion whereas only 1 h was required for 22Cl1 immunoreactivity ( Figure 4 , see also ref. [9] ). This interpretation is based on the assumption that the antibody 22C1 1 is detecting mainly APP in conditioned medium; an alternative interpretation is that 3B1 1 is not as sensitive as 22C1 1. Resolution of this issue awaits separate quantitative data for the two proteins.
Mismetabolism ofAPP has been implicated in the pathogenesis of Alzheimer's disease either as a result of deposition of ,lamyloid or loss of function of secreted APP. Cholinomimetics, currently in clinical trials as antidementia agents, and increased neuronal activity favour non-amyloidogenic APP release in vitro [24] and in vivo [25] . The present study suggests that control of APLP2 release may be similar to that of APP and implies that cholinomimetic treatment of patients with Alzheimer's disease may have a serendipitous effect on the metabolism of both proteins by restoring the secretion of APP and APLP2 and hence their function.
